In the past week, SPRB stock has gone up by 13.42%, with a monthly decline of -82.80% and a quarterly plunge of -69.26%. The volatility ratio for the week is 8.16%, and the volatility levels for the last 30 days are 12.24% for Spruce Biosciences Inc The simple moving average for the past 20 days is -59.80% for SPRB’s stock, with a -64.29% simple moving average for the past 200 days.
Is It Worth Investing in Spruce Biosciences Inc (NASDAQ: SPRB) Right Now?
The 36-month beta value for SPRB is at 2.50. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRB is 21.95M, and currently, shorts hold a 0.86% of that float. The average trading volume for SPRB on April 05, 2024 was 1.25M shares.
SPRB) stock’s latest price update
Spruce Biosciences Inc (NASDAQ: SPRB)’s stock price has plunge by 1.89relation to previous closing price of 0.82. Nevertheless, the company has seen a 13.42% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-27 that Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts’ Opinion of SPRB
Many brokerage firms have already submitted their reports for SPRB stocks, with RBC Capital Mkts repeating the rating for SPRB by listing it as a “Sector Perform.” The predicted price for SPRB in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on March 14, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see SPRB reach a price target of $2, previously predicting the price at $9. The rating they have provided for SPRB stocks is “Market Perform” according to the report published on March 14th, 2024.
SPRB Trading at -75.63% from the 50-Day Moving Average
After a stumble in the market that brought SPRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.89% of loss for the given period.
Volatility was left at 12.24%, however, over the last 30 days, the volatility rate increased by 8.16%, as shares sank -83.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.69% lower at present.
During the last 5 trading sessions, SPRB rose by +13.42%, which changed the moving average for the period of 200-days by -64.74% in comparison to the 20-day moving average, which settled at $1.8703. In addition, Spruce Biosciences Inc saw -71.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRB starting from Novo Holdings A/S, who sale 465,021 shares at the price of $0.75 back on Mar 21 ’24. After this action, Novo Holdings A/S now owns 2,550,000 shares of Spruce Biosciences Inc, valued at $350,951 using the latest closing price.
Novo Holdings A/S, the 10% Owner of Spruce Biosciences Inc, sale 359,979 shares at $0.73 during a trade that took place back on Mar 20 ’24, which means that Novo Holdings A/S is holding 3,015,021 shares at $264,081 based on the most recent closing price.
Stock Fundamentals for SPRB
Current profitability levels for the company are sitting at:
- -5.15 for the present operating margin
- 0.98 for the gross margin
The net margin for Spruce Biosciences Inc stands at -4.72. The total capital return value is set at -0.65. Equity return is now at value -66.10, with -50.55 for asset returns.
Based on Spruce Biosciences Inc (SPRB), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -9.27. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -212.22.
Currently, EBITDA for the company is -51.92 million with net debt to EBITDA at 1.83. When we switch over and look at the enterprise to sales, we see a ratio of -5.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.18.
Conclusion
In conclusion, Spruce Biosciences Inc (SPRB) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
